Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Chemical modification or the reaction product thereof – e.g.,...
Reexamination Certificate
2011-03-15
2011-03-15
Wehbe, Anne Marie S (Department: 1633)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Chemical modification or the reaction product thereof, e.g.,...
C530S350000
Reexamination Certificate
active
07906628
ABSTRACT:
The present invention is directed to compositions comprising an angiogenesis inhibitor coupled to a therapeutic or diagnostic agent. In a specific embodiment, the composition is a fusion gene or fusion gene product encoding the angiogenesis inhibitor coupled to a therapeutic or diagnostic agent. In a particular embodiment, the composition is used for methods to treat angiogenesis-related diseases, such as cancer.
REFERENCES:
patent: 5994104 (1999-11-01), Anderson et al.
patent: 6413513 (2002-07-01), Holaday et al.
patent: 6537554 (2003-03-01), Shimkets et al.
patent: 6552005 (2003-04-01), Buchsbaum et al.
patent: 2002/0090374 (2002-07-01), Yarkoni et al.
patent: WO-99/16889 (1999-04-01), None
patent: WO-9930741 (1999-06-01), None
patent: WO-99/39741 (1999-08-01), None
patent: WO-9947690 (1999-09-01), None
patent: WO-9965515 (1999-12-01), None
patent: WO-0011033 (2000-03-01), None
patent: WO-0071078 (2000-11-01), None
patent: WO-0074629 (2000-12-01), None
patent: WO-0105826 (2001-01-01), None
patent: WO-0151523 (2001-07-01), None
patent: WO-01/87348 (2001-11-01), None
patent: WO-0244328 (2002-06-01), None
Helfrich et al. (2000) J. Immun. Methods, vol. 237, pp. 131-145.
Azar et al. (2000) Apoptosis, vol. 5, 531-542.
Verma et al. (2001) J. Biol. Chem, vol. 276 (7), 4671-4676.
Chen et al. (1999) Cancer Research, vol. 59, pp. 3308-3312.
Scappaticci et al. (2001) Angiogenesis, vol. 4, 263-268.
Gyorffy et al.. (2001) J. Immunology, vol. 166, 6212-6217.
Bowie et al (1990) Science, vol. 247, 1306-1310.
Niethammer, Andreas G., et al.; Targeted Interleukin 2 Therapy Enhances Protective Immunity Induced by an Autologous Oral DNA Vaccine against Murine Melanoma; Cancer Research 61:6178-6184, Aug. 15, 2001.
Dreier, Torsten, et al.; Recombinant Immunocytokines Targeting the Mouse Transferrin Receptor: Construction and Biological Activities; Bioconjugate Chem. 9:482-489, 1998.
Ruehlmann, J. Michael, et al.; MIG (CXCL9) Chemokine Gene Therapy Combines with Antibody-Cytokine Fusion Protein to Suppress Growth and Dissemination of Murine Colon Carcinoma; Cancer Research 61:8498-8503, Dec. 1, 2001.
Lode, Holger N., et al.; Synergy between an antiangiogenic integrin av antagonist and an antibody—cytokine fusion protein eradicates spontaneous tumor metastases; Proc. Natl. Acad. Sci. USA (Medical Sciences) 96:1591-1596, Feb. 1999.
Penichet, Manuel L., et al.; Antibody—cytokine fusion proteins for the therapy of cancer; Journal of Immunological Methods 248:91-101, 2001.
Kreitman, Robert J.; Immunotoxins in cancer therapy; Current Opinion in Immunology 11:590-578,1999.
Holz, Hubert G., et al.; Specific Targeting of Tumor Vasculature by Diphtheria Toxin-Vascular Endothelial Growth Factor Fusion Protein Reduces Angiogenesis and Growth of Pancreatic Cancer; J. Gastrointest Surg 6:159-166, 2002.
Veenendaal, Liesbeth M., et al.; In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors; PNAS 99(12):7866-7871, Jun. 11, 2002.
Scappaticci, Frank A., et al.; Statin-AE: A n ovel angiostatin-endostatin fusion protein with enhanced antiangiogenic and antitumor activity; Angiogenesis 4:263-268, 2001.
Camemolla, Barbara, et al.; Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix; Blood 99:1659-1665, 2002.
Halin, C., et al.; Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature; Nature Biotechnology 20:264-269, Mar. 2002.
Kirsch, Matthias, et al.; Angiogenesis, metastasis, and endogenous inhibition; Journal of Neuro-Oncology 50:173-180, 2000.
Cao, Yihai; Endogenous angiogenesis inhibitors and their therapeutic implications; The International Journal of Biochemistry & Cell Biology 33:357-369, 2001.
Herbst, Roy S., et al.; Phase I Study of Recombinant Human Endostatin in Patients With Advanced Solid Tumors; J Clin Oncol 20(18):1-12, Sep. 15, 2002.
Eder, Jr., Joseph P., et al.; Phase I Clinical Trial of Recombinant Human Endostatin Administered as a Short Intravenous Infusion Repeated Daily; J Clin Oncol 20(18):1-13, Sep. 15, 2002.
Thomas, James P., et al.; Phase I Pharmacokinetic and Pharmacodynamic Study of Recombinant Human Endostatin in Patients with Advanced Solid Tumors; J Clin Oncol 21(2):223-231, Jan. 15, 2003.
Tarabolette, Giulia, et al.; Antiangiogenic and antivascular therapy for cancer; Current Opinion in Pharmacology 1:378-384, 2001.
Boehm, Thomas, et al.; Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance; Nature 390:404-407, Nov. 1997.
Burke, Patricia A., et al.; Antiangiogenic agents and their promising potential in combined therapy; Critical Reviews in Oncology/Hematology 39:155-171, 2001.
Kerbel, Robert S.; Clinical Trials of Antiangiogenic Drugs: Opportunities, Problems, and Assessment of Initial Results; Journal of Clinical Oncology 19(18s):45s- 51s, Sep. 15 Supplement, 2001.
Turner, Richard; Gastric cancer gets the run-around; Nature Medicine 8(5):449, May 2002.
Brem, Steven; Angiogenesis and Cancer Control: From Concept to Therapeutic Trial; Cancer Control 6(5):436-458, 1999.
Huang, Xianming, et al.; Tumor Infarctin in Mice by Antibody-Directed Targeting of Tissue Factor to Tumor Vasculature; Science 275:547-550, Jan. 24, 1997.
Molema, Grietje, et al.; The use of bispecific antibodies in tumor cell and tumor vasculature directed immunotherapy; Journal of Controlled Release 64:229-239, 2000.
Lode, Holger N., et al.; Synergy between an antiangiogenic integrin av antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases; Proc. Nati, Acad. Sci. USA (Medical Sciences) 96:1591-1596, Feb. 1999.
Arora, Naveen, et al.; Vascular Endothelial Growth Factor Chimeric Toxin is Highly Active against Endothelial Cells; Cancer Research 59:183-188, Jan. 1, 1999.
Yang, David J., et al.; Assessment of Antiangiogenic Effect Using 99mTc-EC-Endostatin; Cancer Biotherapy & Radiopharmaceuticals 17(2):233-248, 2002 (date of mailing was May 9, 2002).
Yukihiro, Masashi, et al.; Assessment of angiogenesis using 99mTc-labeled endostatin and angiestatin; Abstract No. 4456, American Association for Cancer Research 2002 Meeting, San Francisco, CA; Abstract available online early Mar. 2002.
Aqueilan, R. S., et al.; Interleukin 2-Bax: A novel prototype of human chimeric proteins for targeted therapy. FEBS Lett, (1999) vol. 457, No. 2, pp. 271-276.
Azar, Y., et al.; GnRH-Bik/Bax/Bak chimeric proteins target and kill adenocarcinoma cells; the general use of pro-apoptotic proteins of the Bcl-2 family as novel killing components of targeting chimeric proteins. Apoptosis (2000) vol. 5, No. 6, pp. 531-542.
Gillies, S.D., et al.; Antibody-IL-12 fusion proteins are effective in SCID mouse models of prostate and colon carcinoma metastases. J. Immunol. (1998), vol. 160, No. 12, pp. 6195-6203.
Lode, H. N., et al. Immunocytokines: a promising approach to cancer immunotherapy. Pharmacol Ther. (1998), vol. 80, No. 3, pp. 277-292.
Henschke et al., “CT screening for lung cancer: update 2005”, Surg Oncol Clin N Am., 2005; 761-76, vol. 14(4).
Johnson-Saliba et al., “Gene therapy: optimising DNA delivery to the nucleus”, Curr Drug Targets, Dec. 2001; 371-99; vol. 2(4).
Niculescu-Duvaz et al., “Recent developments in gene-directed enzyme prodrug therapy (GDEPT) for cancer”, Curr Opin Mol Ther, 1999, 480-6, vol. 1.
Pfeifer et al., “Gene therapy: promises and problems”, Annu Rev Genomics Hum Genet. 2001; 177-211, vol. 2.
Sauter et al., “Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases”, Apr. 25, 2000, 4802-4807, vol. 97(9).
Shoji et al., “Current Status of Delivery Systems to Improve Target Efficacy of Oligonucleotides”, Curr Pharm Des, 2004, pp. 785-796, vol. 10.
Bowie et al., “Deciphering the message in protein sequences: tolerance to amino acid substitutions.” Science. Mar. 16, 1990;247(4948
Hung Mien-Chie
Lan Keng-Hsin
Lan Keng-Li
Liu Jaw-Ching
Yang Fu Ou
Fulbright & Jaworski L.L.P.
The Board of Regents The University of Texas System
Wehbe Anne Marie S
LandOfFree
Targeting proteins to deliver therapeutic or diagnostic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Targeting proteins to deliver therapeutic or diagnostic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Targeting proteins to deliver therapeutic or diagnostic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2638991